Shots:

• Novo Nordisk reports the availability of Esperoct in the US to treat adults and children with hemophilia A as it replaces the clotting Factor VIII that people with hemophilia A are missing and maintains Factor VIII levels longer which help in reducing the frequency of bleeding with less frequent dosing
• In 2019- Esperoct has received the US FDA’s approval based on 5 studies assessing Esperoct (q2w) in 270 patients with hemophilia A and was safe & well tolerated
• Esperoct is an injectable therapy to reduce the number of bleeding episodes in people with hemophilia A. Additionally- Novo Nordisk offers patient assistance program (NovoSecure)- allowing patients administering the therapy to apply for product assistance

Click here to­ read full press release/ article | Ref: Novo Nordisk | Image: The Business Journal